CYRX News and Press, CryoPort Inc. From 05/18/22

Biopharmaceutical stocks have undergone a dramatic correction over the past six months, with the XBI declining by 45%. The decline was appropriate, given the number of companies that went public in 2021 with preclinical data and a valuation exceeding $1 billion. Not only would the...

Cryoport is not just any biotech company, as it is banking on the booming logistic businesses for the cell/gene therapy sector. Leveraging the powerful merger and acquisition approach, Cryoport has been enjoying leaping top-line growth year-over-year. Despite a temporary setback, ...

The following slide deck was published by Cryoport, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Cryoport, Inc. 2022 Q1 - Results - Earnings Call Presentation

Cryoport, Inc. (CYRX) Q1 2022 Earnings Conference Call May 05, 2022 05:00 PM ET Company Participants Todd Fromer - President, KCSA Strategic Communications Jerrell Shelton - CEO Robert Stefanovich - CFO Mark Sawicki - CSO Conference Call Participants John Sourbeer - UBS Brandon Couillard - Je...

CryoPort press release (NASDAQ:CYRX): Q1 GAAP EPS of -$0.31 misses by $0.09. Revenue of $52.3M (-1.8% Y/Y) misses by $0.56M. Provides Full Year 2022 Revenue Guidance of $260-$265 million vs. $257.31M. For further details see: CryoPort GAAP EPS of -$0.31 misses by $0.09, revenue of $52.3...

Cryoport Reports First Quarter 2022 Results PR Newswire Revenue of $52.3 million Provides Full Year 2022 Revenue Guidance of $260 - $265 million Expansion and advancement of robust clinical pipeline continues – now supporting a reco...

Cryoport to Report First Quarter 2022 Financial Results on May 5, 2022 PR Newswire NASHVILLE, Tenn. , April 28, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain s...

A turnaround plays are highly risky yet you found them in the land of multi-baggers. BioLife shares have tumbled substantially due to various issues like supply-chain that cannot keep pace with the company's growth by acquisition strategy. There are also management changes and the...

Cryoport (NASDAQ:CYRX), a provider of logistics and supply chain solutions for the life sciences industry, on Monday said it acquired Cell&Co BioServices, a business providing biorepository, kitting, and logistics services. CYRX's purchase price for Cell&Co was €6.2M, comprised...

Cryoport Acquires Cell&Co BioServices Cryoport Acquires Cell&Co BioServices PR Newswire Acquisition of Cell&Co BioServices, Clermont-Ferrand , France, accelerates Company's EMEA expansion plans and development of its Global Supply Chain Network...